Terms: = Lymphoma AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Treatment
8 results:
1. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic lymphoma Kinase Inhibitor.
Gupta N; Hanley MJ; Griffin RJ; Zhang P; Venkatakrishnan K; Sinha V
Clin Pharmacokinet; 2023 Aug; 62(8):1063-1079. PubMed ID: 37493887
[TBL] [Abstract] [Full Text] [Related]
2. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.
Altés A; Paré L; Esquirol A; Xicoy B; Rámila E; Vicente L; López R; Orriols J; Vall-llovera F; Sánchez-González B; del Río E; Sureda A; Páez D; Baiget M
Leuk Lymphoma; 2013 Aug; 54(8):1706-12. PubMed ID: 23323945
[TBL] [Abstract] [Full Text] [Related]
4. Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).
Fredenhagen A; Kittelmann M; Oberer L; Kuhn A; Kühnöl J; Délémonté T; Aichholz R; Wang P; Atadja P; Shultz MD
Drug Metab Dispos; 2012 May; 40(5):1041-50. PubMed ID: 22344701
[TBL] [Abstract] [Full Text] [Related]
5. Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.
da Silva Silveira V; Canalle R; Scrideli CA; Queiroz RG; Bettiol H; Valera ET; Tone LG
Leuk Res; 2009 Jul; 33(7):898-901. PubMed ID: 19162321
[TBL] [Abstract] [Full Text] [Related]
6. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract] [Full Text] [Related]
7. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia.
Krajinovic M; Labuda D; Mathonnet G; Labuda M; Moghrabi A; Champagne J; Sinnett D
Clin Cancer Res; 2002 Mar; 8(3):802-10. PubMed ID: 11895912
[TBL] [Abstract] [Full Text] [Related]
8. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry M; Gibbons S; Back D; Mulcahy F
Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
[TBL] [Abstract] [Full Text] [Related]
